Pin Wang, PhD

Professor

Image of Pin Wang, PhD
Is this your profile? Click to edit

Overview

The Wang laboratory focuses on an emerging field of “immunobioengineering” with the aim of employing engineering tools and principles to quantitatively understand the immune system in health and disease and to develop novel molecular and cellular immunotherapies by precisely modulating disease-specific immune responses. The ongoing research research projects include: 1) exploring various strategies to engineer virus-derived vector systems for dendritic cell-targeted vaccine delivery and oncolytic virus-based immunotherapy; 2) designing and optimizing cellular immunotherapy that is based on molecular engineering of chimeric antigen receptors (CARs); 3) exploring immune cells as drug carriers for targeted delivery of immunomodulatory drugs to enhance cancer immunotherapy; 4) exploring systems biology tools for modeling and understanding details of signaling pathways mediated by designer molecules such as chimeric antigen receptors to activate T cells; 5) developing engineering methods to improve adeno-associated virus (AAV)-based gene delivery. In this research laboratory, bioengineers collaborate with chemists, immunologists, computer scientists, and system biologists to directly address problems in translational immunology and develop and optimize innovative approaches to improve lives of patients suffering from cancer and infectious diseases.

Research Funding

  • In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.
    NIH · R01EB017206 · Sep 1, 2013 – Aug 31, 2020 · Role: Co-Principal Investigator
  • SUPR Peptides to Inhibit Undruggable Cancer Target (PQ18)
    NIH · R01CA170820 · Sep 17, 2012 – Jun 30, 2017 · Role: Co-Principal Investigator
  • Targeting lentiviruses to infect chosen cells
    NIH · R01AI068978 · Feb 1, 2006 – Jan 31, 2012 · Role: Principal Investigator

Research Keywords

  • Cancer Immunotherapy
  • Immunoengineering
  • T Cell Engineering
  • Chimeric Antigen Receptor
  • Cancer Vaccine
  • Gene Therapy
  • Immuno-Oncology

Publications

  • Engineered lentiviral vectors pseudotyped with a CD4 receptor and a fusogenic protein can target cells expressing HIV-1 envelope proteins. Virus Res. 2011 Sep; 160(1-2):340-50.. View in PubMed
  • Virus-receptor mediated transduction of dendritic cells by lentiviruses enveloped with glycoproteins derived from Semliki Forest virus. PLoS One. 2011; 6(6):e21491.. View in PubMed
  • Pseudotyping lentiviral vectors with aura virus envelope glycoproteins for DC-SIGN-mediated transduction of dendritic cells. Hum Gene Ther. 2011 Oct; 22(10):1281-91.. View in PubMed
  • Redox-responsive nanocapsules for intracellular protein delivery. Biomaterials. 2011 Aug; 32(22):5223-30.. View in PubMed
  • Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates. ACS Nano. 2011 May 24; 5(5):3523-35.. View in PubMed
  • Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma. Cancer Gene Ther. 2011 May; 18(5):370-80.. View in PubMed
  • Gene editing of human embryonic stem cells via an engineered baculoviral vector carrying zinc-finger nucleases. Mol Ther. 2011 May; 19(5):942-50.. View in PubMed
  • Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian cells. J Biol Eng. 2011 Jan 28; 5(1):1.. View in PubMed
  • Endoprotease-mediated intracellular protein delivery using nanocapsules. ACS Nano. 2011 Feb 22; 5(2):1385-94.. View in PubMed
  • Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev. 2011 Jan; 239(1):45-61.. View in PubMed